Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
For California residents in the top tax brackets, the Invesco California AMT-Free Municipal Bond ETF PWZ continues to...
Billionaire investor Mark Cuban argues the current economics of AI agents create a meaningful short-term counter to j...
AI data centers are driving a new energy challenge as grid bottlenecks stall growth. Off-grid, flameless generators a...
Novo Nordisk stock investors faced volatility after softer results and cautious guidance, but momentum around Wegovy ...
Two chipmakers lit up the market in the first half of 2026, but the big question remains: which is the smarter buy no...
A private defense contractor is pushing the Navy toward autonomous, unmanned surface ships. This article explains the...
US spot Bitcoin ETFs posted another day of outflows on June 30, extending a nine-day streak and signaling a broader c...
Two private-credit funds unveiled exit options for locked-up investors, offering steep discounts and renewed liquidit...
A bold nonprofit initiative pairs BitMine and Sharplink with Joe Lubin to speed Wall Street's entry into Ethereum's o...
A brutal 2022 bond selloff upended the notion that fixed income always delivers safety. With inflation stubborn and r...
Nike delivered a quarterly beat that sent its shares higher, but investors kept a close eye on tariffs and future gui...